Sandra Calvin - 24 Jan 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role: VP, Corp Controller and CAO
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol: TVTX
Transactions as of: 24 Jan 2022
Net transactions value: -$22,955
Form type: 4
Filing time: 26 Jan 2022, 15:38:39 UTC
Previous filing: 23 Sep 2021
Next filing: 02 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TVTX	Common Stock	Sale	$22,955	-934	-3.2%	$24.58	28,662	24 Jan 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F2	Includes 842 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program.

Content

Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Includes 842 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program.